Biotech Analyst Zelin discusses JANX007 (Janux Therapeutics (JANX)) and the evolving prostate cancer landscape on an Analyst/Industry conference call to be held on October 21 at 2 pm.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics Announces Departure of Chief Strategy Officer
- Janux Therapeutics initiated with an Overweight at Barclays
- Synopsys downgraded, Oracle upgraded: Wall Street’s top analyst calls
- Janux Therapeutics initiated with a Buy at Truist
- Buy Rating for Janux Therapeutics Inc: Promising Oncology Innovations and Strategic Advancements